Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

The MYC Oncogene Initiates and Maintains Metastasis in Mouse Prostate Cancer Model

By BiotechDaily International staff writers
Posted on 12 Feb 2014
Image: Shown here is a tumor that metastasized from its original site in the prostate to the lung. Researchers were surprised to find the Myc protein in these tumors and, through further experiments, discovered that simply increasing the amount of Myc in the cell was enough to drive metastasis, suggesting a druggable target for metastatic prostate cancer (Photo courtesy of Cold Spring Harbor Laboratory).
Image: Shown here is a tumor that metastasized from its original site in the prostate to the lung. Researchers were surprised to find the Myc protein in these tumors and, through further experiments, discovered that simply increasing the amount of Myc in the cell was enough to drive metastasis, suggesting a druggable target for metastatic prostate cancer (Photo courtesy of Cold Spring Harbor Laboratory).
A mouse metastatic prostate cancer model is expected to enable researchers to better investigate the causes of the disease while at the same time test new therapeutics to treat it.

The RapidCaP genetically engineered mouse (GEM) system was developed by investigators at Cold Spring Harbor Laboratory (NY, USA) who injected viral genes directly into mouse prostate tumors in order to induce them to metastasize.

Examination of these animals and analysis at the molecular level revealed that PI 3-kinase activity, a well-known modulator of prostate cancer, was absent from the RapidCaP metastasized tumors, and that the MYC oncogene was acting as the driving force behind the spread of the tumor. Indeed, they found that prostate tumors could be driven to metastasize simply by increasing the amount of Myc protein.

MYC (v-myc myelocytomatosis viral oncogene homolog protein) is a transcription factor that activates expression of a great number of genes through binding on consensus sequences and recruiting histone acetyltransferases (HATs). By acting as a transcriptional repressor in normal cells, MYC has a direct role in the control of DNA replication. The MYC protein (c-Myc) is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis, and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement, and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias, and lymphomas, including Burkitt lymphoma.

The investigators used RapidCaP to show that Myc both triggered local prostate metastasis and was critical for its maintenance. They further reported in the January 20, 2014, online edition of the journal Cancer Discovery that by treating these animals with the drug JQ1, which reduces the amount of Myc in cells, they could shrink the metastases, suggesting that the switch to Myc was required for maintenance of tumor cells that have metastasized throughout the body.

“The RapidCaP system has revealed a specific role for Myc as a druggable driver of metastasis in prostate cancer,” said senior author Dr. Lloyd Trotman. “So there is hope that our model provides a fast and faithful test-bed for developing new approaches to cure the type of prostate cancer that today is incurable.”

Related Links:

Cold Spring Harbor Laboratory



Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.